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Abstract: Acute heart failure (AHF) is a major cause of hospitalizations. Severe dyspnea, 
pulmonary congestion and low cardiac output with peripheral vasoconstriction and renal 
hypoperfusion is a main form of clinical presentation. Most patients with acute worsening have 
a pre-existing decompensated chronic heart failure (ADCHF), but AHF may also occur as a ﬁ  rst 
manifestation of a previously unknown heart disease. Myocardial ischemia, cardiac arrhythmias, 
non-compliance with medication and infections are frequent precipitating factors. Management of 
AHF depends on the underlying heart disease and cause of decompensation. In patients with ADCHF 
vasodilators and iv diuretics are ﬁ  rst-line drugs for rapid reduction of dyspnea and congestion. In 
patients with signs of low cardiac output and oliguria, inotropic agents are also often administered 
to prevent further deterioration. Beta-adrenergic agents and phosphodiesterase inhibitors correct 
the hemodynamic disturbance, but may also induce arrhythmias and worsen myocardial ischemia. 
Inotropic therapy therefore remains controversial. A novel class of drugs, the calcium sensitizers, 
represent a new therapeutic option. Levosimendan was shown to improve myocardial contractility 
without increasing oxygen requirements and to produce peripheral and coronary vasodilation. Its 
therapeutic effects and tolerance have been tested in several trials. The present review focuses on 
the clinical pharmacology and therapeutic utility of levosimendan in patients with ADCHF.
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Introduction
Therapeutic guidelines have been primarily developed for patients with chronic heart failure 
(CHF). Recommendations are based on large scale trials with angiotensin-converting 
enzyme (ACE) inhibitors, angiotensin receptor antagonists and beta-blockers conducted 
in symptomatic patients with reduced left ventricular ejection fraction, usually  35% to 
40%, in a stable phase. More recently, attention also turned to acute and worsening heart 
failure which is a major cause of hospitalizations. Several epidemiological surveys in 
Europe1–4 and in the USA5 described the demographics, symptoms, physical ﬁ  ndings and 
precipitating factors of AHF. A classiﬁ  cation according to the initial clinical presentation 
was proposed by the European Society of Cardiology.6 In EuroHF II2 acute decompensa-
tion of a pre-existing CHF (ADCHF) with signs of pulmonary congestion and low cardiac 
output was the most frequent form of AHF, occurring in 65% of patients, followed by 
pulmonary edema (16%), HF and hypertension (11%), cardiogenic shock (4%) and right 
HF (3%). In about 30% of cases AHF was the ﬁ  rst (de novo) manifestation of a previously 
unknown cardiac disease. Patients with AHF require urgent therapeutic measures to reduce 
symptoms, improve the hemodynamic disturbancies and prevent further deterioration. 
Thus, drug choices, dosages and mode of administration may considerably differ from 
those in CHF where treatment can be adjusted over a longer period.
Therapeutic options in ADCHF
The initial management of AHF depends on the underlying cardiac disease, preceding 
drug treatment and precipitating factors. If present, hypertension, arrhythmias or acute Drug Design, Development and Therapy 2009:3 74
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coronary syndromes have to be treated ﬁ  rst as soon as possible. 
Among the symptomatic measures to improve dyspnea and 
relieve congestion vasodilators and/or high ceiling diuretics 
are usually the drugs of initial choice. Nitroglycerine or 
isosorbide dinitrate iv have been shown to be superior to 
repeated high doses of furosemide in patients with pulmo-
nary edema.7 One of the disadvantages of nitrates is a loss of 
efﬁ  cacy due to tachyphylaxis within the ﬁ  rst 24 to 48 hours. 
A new alternative for vasodilation is nesiritide, a brain natri-
uretic peptide (BNP) analogon, which has effects comparable 
to nitroglycerin without reduction of activity during prolonged 
administration.8 This drug has been widely used in the USA, 
but there were negative reports concerning a worsening renal 
function9 and a trend to higher mortality under nesiritide.10
Although the increased risks have been partly refuted by a 
retrospective analysis11 the ﬁ  nal value of nesiritide needs to be 
evaluated in further trials. If pulmonary congestion does not 
rapidly respond to drug treatment a noninvasive positive pres-
sure ventilation by a face mask is a well documented effective 
therapeutic measure in AHF with pulmonary edema.12
One of the controversial issues in ADCHF is the use of 
inotropic agents. If signs of low cardiac output with peripheral 
vasoconstriction and oliguria persist despite correction or 
exclusion of a hypovolemia and patients do not respond to 
vasodilators and diuretics, an improvement of myocardial 
contractility might be needed to correct the severe cardio-
vascular dysfunction. For this reason beta-adrenergic drugs, 
dobutamine and dopamine, or phosphodiesterase inhibitors, 
milrinone and enoximone, are often administered. Although 
these agents produce a symptomatic and hemodynamic 
improvement, their inﬂ  uences on clinical outcomes are mostly 
negative. Increased myocardial oxygen requirements and 
pro-arrhythmia are well known undesired effects which may 
seriously compromise the utility of inotropic therapy.13–15
A new category of cardio-stimulant drugs with combined 
positive inotropic and vasodilating effects, the calcium sensi-
tizers, may avoid some of the disadvantages of other inotropic 
agents and offer a therapeutic alternative in patients with 
ADCHF. Levosimendan is the best studied calcium sensitizer 
and is available for routine clinical use in several European coun-
tries, as well as in Brasil, Argentina and Mexico. This review 
will focus on the clinical pharmacology of levosimendan, its 
dosage, indications and analyze the results of clinical trials.
Clinical pharmacology 
of levosimendan
The positive inotropic action of levosimendan is due to 
its binding to troponin C which facilitates the interaction 
between actin and myosine ﬁ  laments without changes in 
intracellular Ca++ ion concentrations.16 In addition, the drug 
produces peripheral and coronary vasodilation by opening 
ATP-sensitive potassium channels.17 This dual mechanism 
of action results in an improved myocardial contractility 
without relevant changes in oxygen requirements18 and in a 
reduction of post-ischemic stunning.19,20
The pharmacokinetic and pharmacodynamic properties 
of levosimendan have been studied in healthy volunteers 
and patients with heart failure.21,22 Following intravenous 
administration in different dosages the pharmacoki-
netics remained linear with an elimination half-life of 
the unchanged compound of around 1 hour. Complete 
metabolism with formation of two pharmacologically 
active products (OR-1896 and OR-1855) is the mechanism 
of hepatic excretion. These metabolites are eliminated very 
slowly with half-lives of  80 and  70 hours, respectively. 
Because their activity is similar to that of levosimendan the 
pharmacodynamic effects of a 24-hour infusion last up to 
several days.23 For this reason more prolonged infusions 
are not recommended. In patients with heart failure and 
mild to moderate renal dysfunction, pharmacokinetics 
changed little, but in patients with end-stage renal 
disease undergoing hemodialysis, an accumulation of the 
active metabolites could be observed.24 Thus, initial dose 
reduction (starting with 0.05 μg/kg/min) is necessary if 
levosimendan is used in patients with ADCHF and renal 
dysfunction. There are few data available on the extent of 
metabolite accumulation in patients with liver disease.25 
In 12 cases with alcoholic cirrhosis there was a slight 
prolongation of metabolite half-lives (+30%), which would 
again indicate lower initial infusion rates, similar to those 
in patients with renal failure.
The hemodynamic effects of levosimendan have been 
evaluated in dose ﬁ  nding studies in patients with CHF.26 
After initial iv bolus infusions of 3, 6, 12, 24 or 36 μg/kg 
in 10 minutes, followed by 24-hour continuous infusions at 
rates of 0.05, 0.1, 0.2, 0.4 and 0.6 μg/kg/min, dose-dependent 
increases of cardiac output and stroke volume together with 
a rapid decreases of pulmonary capillary wedge pressure 
and right atrial pressure were measured. Slight heart rate 
increases and reductions in mean blood pressure were also 
seen. Calculated peripheral vascular resistance was linearly 
reduced with increasing doses. Protocol defined dose 
limiting events were tachycardia  20% and systolic blood 
pressure  90 mmHg, mainly in patients receiving higher 
doses of 0.4 and 0.6 μg/kg/min. Headaches and nausea also 
occurred in some cases. Based on this study infusion rates Drug Design, Development and Therapy 2009:3 75
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of 0.05 to 0.2 μg/kg/min were recommended to achieve 
favorable hemodynamic effects with good tolerance.
Clinical trials with levosimendan
The ﬁ  rst randomized, double-blind, multicenter trial (LIDO) 
compared levosimendan with dobutamine in 203 hospitalized 
patients with severe low output CHF.27 Inclusion criteria were 
an ejection fraction  35%, a cardiac index  2.5 L/min/m2 
and a pulmonary capillary wedge pressure  15 mmHg. All 
patients were symptomatic under a treatment with ACE 
inhibitors, diuretics and digoxin; one third also received 
a beta-blocker. Levosimendan was infused after a loading 
dose of 24 μg/kg/min in 10 minutes at a rate of 0.1 μg/kg/min 
for 24 hours and dobutamine without loading at 5 μg/kg/min. 
Dosage of both drugs was doubled after 2 hours if the 
intended hemodynamic improvement, deﬁ  ned as increase of 
cardiac index by 30% and reduction of pulmonary capillary 
wedge pressure by 25%, was not achieved. This end-point 
was reached in 28% of patients with levosimendan com-
pared to only 15% with dobutamine (p   0.022). In the 
subgroup of patients under beta-blockade therapeutic targets 
were obtained in 10 out of 33 under levosimendan versus 
3 of 29 cases under dobutamine, respectively. Furthermore, 
levosimendan also had a beneficial effect on clinical 
outcomes: at 31 days mortality was lower after levosimen-
dan with 8 deaths (8%) versus 17 (17%) after dobutamine 
(hazard ratio 0.43 [0.18–1.0], p = 0.049). The prognostic 
beneﬁ  t persisted up to 180 days, the median number of 
days alive and out of hospital being 157 (101–173) in the 
levosimendan group and 133 (43.5–169) after dobutamine 
(p = 0.027). The total number of adverse events was compa-
rable in both treatment groups (48 vs 42 events, p 0.88), but 
more arrhythmias14 occurred under dobutamine than under 
levosimendan,4 p   0.023, while hypotension was observed 
in 9 patients under levosimendan compared to 4 under dobu-
tamine (p = 0.252). Thus, there was an overall advantage of 
levosimendan in this trial.
The second randomized clinical trial (RUSSLAN) 
compared levosimendan, infused for 6 hours in 4 different 
doses, with placebo in 504 patients with clinical and radio-
logical signs of left ventricular failure following an acute 
myocardial infarction.28 The primary aim was to test the 
tolerability of levosimendan with the end-points hypotension 
and myocardial ischemia. Secondary end-points included 
all cause mortality and worsening HF. At doses of 0.1 to 
0.2 μg/kg/min levosimendan did not increase the incidence 
of hypotension or ischemia and reduced the combined risk of 
death and worsening HF during the ﬁ  rst 24 hours (4% versus 
8.8% in the placebo group, p = 0.044). There was, however, 
a non-signiﬁ  cant trend for a higher risk of hypotension and/or 
ischemia at the highest dose (0.4 μg/kg/min) of levosimendan. 
Mortality at 14 days was 19.6% after placebo compared 
to 10.0% to 13.1% (average 11.7%) in the four subgroups 
receiving levosimendan (p = 0.031), but after 180 days the 
differences were no more statistically signiﬁ  cant.
More recently, two larger randomized, double-blind trials 
were conducted in the USA and in Europe. In REVIVE II, 
24-hour infusions of levosimendan were compared with 
placebo in 600 patients with ADCHF.29 The primary 
‘composite’ end-point was a measure of the clinical course, 
based on subjective and objective symptom assessments 
over 5 days. Levosimendan was given after an initial loading 
of 12 μg/kg in 10 minutes followed by a uniform infusion 
rate of 0.2 μg/kg/min for 24 hours. Co-administration of iv 
diuretics and vasodilators was allowed without hemodynamic 
monitoring. At 5 days 33% more patients improved and 26% 
fewer worsened after levosimendan than placebo (p = 0.015). 
This positive clinical outcome was, however, partially 
neutralized by a high incidence of hypotension (50.2 vs 36.4%, 
p   0.01) and more frequent atrial ﬁ  brillation (8.5 vs 2.0%) 
under levosimendan and placebo, respectively. There was 
also a non-signiﬁ  cant negative trend for higher mortality at 
14 and 31 days following levosimendan. The SURVIVE trial30 
compared levosimendan with dobutamine in 1327 patients 
with acute heart failure judged to require inotropic support. 
Again, levosimendan was given in a uniform high dosage at 
0.2 μg/kg/min to all patients for 24 hours; the average dose 
of dobutamine was 6 μg/kg/min. Patients were hospitalized at 
intensive care units but not invasively monitored. Also in this 
trial iv diuretics and concomitant vasodilators were allowed. 
The primary end-point was survival at 180 days. At the end 
of follow up there were 173 deaths (26%) in the levosimen-
dan group as compared to 185 (28%) on placebo (p = 0.4). 
However, a subgroup analysis at 31 days showed a survival 
advantage of levosimendan in patients with a prior history of 
heart failure. Also plasma BNP levels decreased signiﬁ  cantly 
more at 24 hours and at 3 to 5 days after levosimendan than 
after dobutamine. The rates of serious adverse events were 
not different in the two treatments groups, but there were 
more hypotensions and higher heart rate increases under 
levosimendan, while patients were less likely to experience 
worsening cardiac failure than under dobutamine.
Following the presentation of REVIVE II and SURVIVE 
doubts were voiced regarding the utility of levosimendan 
in the treatment of AHF.31 For this reason it is important to 
analyze the basic differences between the initially positive Drug Design, Development and Therapy 2009:3 76
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and the more recent partly contradictory trial results and 
try to explain the variable outcomes. In the LIDO trial all 
patients were hemodynamically monitored and had initial 
capillary wedge pressures of 15 mmHg or more (mean 
25 ± 8 mmHg), as well as a cardiac index  2.5 L/kg/m2. 
Thus, they all belonged to a well deﬁ  ned category of ADCHF 
patients; cases with signs of active myocardial ischemia or 
acute arrhythmias were excluded. Co-administration of iv 
diuretics or vasodilators was not allowed. In contrast, both 
in REVIVE and SURVIVE, simultaneous treatment with 
the above drugs, often at high doses, was permitted without 
invasive monitoring. Hence, a drug-induced hypovolemia 
could not be excluded and was probably present in many 
cases. The high incidence of hypotension (36.4%) even 
under placebo in REVIVE II would ﬁ  t this assumption. 
Administering levosimendan, with its marked vasodilating 
effect at high and uniform doses, especially to heavily pre-
treated patients, can be expected to result in marked drops 
in blood pressure and also lead to cardiac arrhythmias in 
patients with an underlying coronary artery disease which 
in SURVIVE was present in over 60%. Hypokalemia due 
to intensive diuretic administration was an other potentially 
negative factor. Thus, in retrospect the design in both trials 
can be questioned. The main lesson from these two recent 
trials is that a high initial infusion rate of levosimendan has 
to be avoided and pre-existing hypovolemia be excluded 
before starting this treatment. In critical cases, especially 
with systolic blood pressure values   100 mmHg, infusion 
should be initiated without loading at only 0.05 μg/kg/min 
under close observation to avoid severe hypotension.
Levosimendan in routine 
clinical practice
There are also observational studies available documenting 
the practical experience with levosimendan in everyday 
practice. A Brazilian cohort32 including 182 high risk patients 
with decompensated HF received open label levosimendan 
infusions added to a baseline treatment with diuretics, ACE 
inhibitors/angiotensin receptor antagonists and beta-blockers. 
In 39% inotropic agents were already used before without 
success. Out of the 182 patients 139 (76.4%) responded, 
deﬁ  ned by reduction of dyspnea and of auscultatory signs 
of pulmonary congestion and could be discharged from hos-
pital. Treatment success was even better (83.3%) in patients 
on beta-blockers (21%). Levosimendan was said to be well 
tolerated; no severe hypotension or an increase in cardiac 
arrhythmias occurred. Nevertheless, 54 patients had some 
adverse events which resolved spontaneously or after dose 
reduction. Mortality rate during hospitalization was 14.8% 
in patients responding to levosimendan compared to 62.8% 
in non-responders. A similar positive practical experience 
was reported from Portugal.33 In an open, prospective, 
multicenter study in 129 hospitalized patients with systolic 
HF and signs of decompensation, a 24-hour infusion of 
levosimendan at a dose of 0.05 to 0.1 μg/kg/min was given 
as a ﬁ  rst line inotropic therapy. During an observation period 
of 5 days a well deﬁ  ned clinical improvement (reduction of 
NYHA class and increased diuresis with reduction of serum 
creatinine) without additional inotropes and no adverse events 
was obtained in 80%. These observational data indicate that 
levosimendan can be safely and successfully used under 
everyday routine clinical conditions.
Levosimendan and renal function
An important advantage of levosimendan is its potential 
to improve renal function in patients with ADCHF. A 
signiﬁ  cant reduction of serum creatinine was reported already 
in the initial clinical trial.27 Subsequently, two studies were 
specially conducted to evaluate the effects of levosimendan 
on serum creatinine and glomerular ﬁ  ltration rate (GFR). 
In 40 patients with advanced CHF and increased serum 
creatine values (1.92 ± 0.13 mg/dL), a 24-hour infusion at a 
dose of 0.1 ± g/kg/min compared to a control group without 
inotropic support, but otherwise identical treatment, showed 
a reduction of serum creatinine by −0.32 ± 0.28 mg/dL 
and −0.01 ± 0.13 mg/dL, respectively.34 After 3 months 
creatinine clearance was still improved from the initial 
value of 43.7 ± 2.9 mL/min to 53.6 ± 8.6 mL/min, whereas 
in the control group GFR did not change. In another study 
levosimendan was compared with dobutamine, both infused 
for 24 hours, in 88 consecutive patients with ADCHF.35 Within 
24 hours GFR increased by 15.3% under levosimendan versus 
−1.33% under dobutamine. GFR values improved further 
after 72 hours.
Effects of levosimendan 
on surrogate end-points in HF
Levosimendan was also shown in smaller comparative trials 
to have potentially beneﬁ  cial effects not only on neurohor-
mones, but also on inﬂ  ammatory cytokines and apoptosis 
mediators in HF. Moertl et al36 observed a BNP reduction by 
28% at 24 hours and by 22% at 48 hours following 24 hours 
levosimendan infusion in patients with decompensated 
HF, but these effects disappeared after 1 week. Parissis 
et al37 reported a signiﬁ  cant BNP reduction together with 
further reduction of interleukin-6 (IL-6). In their patients Drug Design, Development and Therapy 2009:3 77
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there was also an improvement of left ventricular diastolic 
function as judged by echocardiographic techniques. Trikas 
et al38 equally found signiﬁ  cant decreases of serum IL-6, 
TNF-alfa as well as of the apoptosis marker soluble FAS 
(sFAS). Such surrogate effects could have positive long-term 
therapeutic inﬂ  uences for levosimendan in addition to its 
cardio-stimulatory activity, but convincing clinical data in 
this respect are still lacking.
Emerging indications 
and treatments
There are also some new indications for levosimendan 
treatment, such as repetitive administration in patients with 
advanced HF,39,40 post-operative myocardial dysfunction 
following cardiac surgery,41 or right ventricular failure.42 
These interesting applications require further larger trials to 
conﬁ  rm the therapeutic utility of levosimendan.
The recently developed new inotropic and lusitropic agent, 
istaroxime, which has similar hemodynamic effects and also 
does not seem to increase myocardial oxygen requirements,43 
might become a potential alternative to levosimendan in 
patients with HF, but the clinical data are still limited.
Conclusions
Current indications and dosage 
recommendations for levosimendan
Levosimendan represents a new and valuable option for the 
treatment of properly selected and monitored patients with 
decompensated heart failure needing inotropic support to 
prevent further deterioration. The best documented indication 
for levosimendan is the treatment of patients with ADCHF 
presenting with high ﬁ  lling pressures, signs of congestion 
and reduced cardiac output with peripheral vasoconstriction. 
The combined inodilating effects of levosimendan rapidly 
relieve pulmonary congestion and improve organ perfusion, 
including renal blood flow and GFR. However, before 
starting a levosimendan infusion it is essential to exclude 
and correct a hypovolemia due to preceding high dose iv 
diuretics or vasodilators, otherwise an arterial hypotension 
may occur. Low serum potassium should also be corrected 
to avoid proarrhythmic effects.
Based on clinical experience in countries in which use is 
widespread, a loading dose of levosimendan can be omitted 
in many patients, especially if the initial systolic blood 
pressure is  100 mmHg. In view of the short (1 hour) half-
life of unchanged levosimendan a near maximum effect of 
a given infusion rate will be reached within 4 hours without 
loading. A starting infusion rate of 0.05 μg/kg/min is usually 
safe even in critical patients. The dose can be increased to 
0.1 μg/kg/min after 1 to 2 hours if the drug is well tolerated; 
0.2 μg/kg/min might be needed in some patients not adequately 
responding. The standard duration of infusion is 24 hours, 
but in some situations, such as intermittent ambulatory 
administration, a 6- to 8-hour infusion may be more suitable. 
A prolonged infusion is not recommended, since the slowly 
formed active metabolites maintain the hemodynamic effects 
for several days and longer treatments lead to drug accumula-
tion with tachycardia and hypotension.42
The best efﬁ  cacy can be expected in patients pre-treated 
with beta-blockers which, in contrast to beta-adrenergic 
drugs, do not reduce the actions of levosimendan. In patients 
not yet under beta-blockers these drugs can be safely intro-
duced and uptitrated under protection with levosimendan 
even after an episode of acute decompensation.
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